Symptomatic Bradycardia Associated with Topical Brimonidine Gel (Mirvaso) Administration: A Case Report

D. Jesudason, Nageswary Appalanaidu, Asif Khan
{"title":"Symptomatic Bradycardia Associated with Topical Brimonidine Gel (Mirvaso) Administration: A Case Report","authors":"D. Jesudason, Nageswary Appalanaidu, Asif Khan","doi":"10.1093/ehjcr/ytae329","DOIUrl":null,"url":null,"abstract":"\n \n \n Bradycardias can have a number of different aetiologies, including as a side-effect of medications. Brimonidine is a rare, but recognised, cause of bradycardia. Brimonidine is indicated in the treatment of facial erythema in rosacea when given as topical brimonidine gel (Mirvaso). It may also be administered as eye drops for raised intraocular pressure in open angle glaucoma and ocular hypertension. Brimonidine is an alpha-2 agonist, which if systemically absorbed can present with bradycardia, hypotension and dizziness. The authors are unaware of any other case reports regarding topical administration of Mirvaso in an adult and symptomatic bradycardia.\n \n \n \n We present the case of a 78 year old man with a background of rosacea, benign prostatic hyperplasia and hypertension who had two separate admissions with symptomatic bradycardia. Electrocardiograms showed sinus bradycardia with AV block 1st degree, with rate recorded as low as 31 bpm during a syncopal episode. These episodes of symptomatic bradycardia were intermittent and had a temporal association with topical administration of Mirvaso. He had no further episodes of bradycardia on discontinuation of Mirvaso and has remained symptom free for over six months.\n \n \n \n The topical administration of Mirvaso should be avoided to broken or inflamed skin. This is owing to the increased risk of systemic absorption, which as in this case report, may present with bradycardia. This case reiterates the importance of completing a full medication history including of all topical and parenteral medications in patients with arrhythmia.\n","PeriodicalId":507701,"journal":{"name":"European Heart Journal - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ehjcr/ytae329","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Bradycardias can have a number of different aetiologies, including as a side-effect of medications. Brimonidine is a rare, but recognised, cause of bradycardia. Brimonidine is indicated in the treatment of facial erythema in rosacea when given as topical brimonidine gel (Mirvaso). It may also be administered as eye drops for raised intraocular pressure in open angle glaucoma and ocular hypertension. Brimonidine is an alpha-2 agonist, which if systemically absorbed can present with bradycardia, hypotension and dizziness. The authors are unaware of any other case reports regarding topical administration of Mirvaso in an adult and symptomatic bradycardia. We present the case of a 78 year old man with a background of rosacea, benign prostatic hyperplasia and hypertension who had two separate admissions with symptomatic bradycardia. Electrocardiograms showed sinus bradycardia with AV block 1st degree, with rate recorded as low as 31 bpm during a syncopal episode. These episodes of symptomatic bradycardia were intermittent and had a temporal association with topical administration of Mirvaso. He had no further episodes of bradycardia on discontinuation of Mirvaso and has remained symptom free for over six months. The topical administration of Mirvaso should be avoided to broken or inflamed skin. This is owing to the increased risk of systemic absorption, which as in this case report, may present with bradycardia. This case reiterates the importance of completing a full medication history including of all topical and parenteral medications in patients with arrhythmia.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
局部使用溴莫尼定凝胶(Mirvaso)引起的症状性心动过缓:病例报告
心动过缓有多种不同的病因,包括药物的副作用。溴莫尼定是导致心动过缓的一种罕见但公认的原因。溴莫尼定以局部使用溴莫尼定凝胶(Mirvaso)的形式用于治疗红斑痤疮的面部红斑。溴莫尼定还可以作为眼药水用于治疗开角型青光眼和眼压过高引起的眼压升高。溴莫尼定是α-2受体激动剂,如果被全身吸收,会出现心动过缓、低血压和头晕。作者不知道是否有其他病例报告称成人局部使用 Mirvaso 会出现心动过缓症状。 我们介绍了一例 78 岁的男性病例,他患有酒渣鼻、良性前列腺增生症和高血压,曾两次因症状性心动过缓入院。心电图显示窦性心动过缓伴有 1 度房室传导阻滞,在一次晕厥发作时,记录到的心率低至 31 bpm。这些症状性心动过缓的发作是间歇性的,与局部使用米瓦索有时间上的联系。停用米尔伐索后,他没有再出现心动过缓的症状,至今已六个多月无症状。 应避免在破损或发炎的皮肤上局部使用 Mirvaso。这是因为全身吸收的风险增加,在本病例报告中可能会出现心动过缓。本病例再次强调了为心律失常患者提供完整用药史的重要性,包括所有局部用药和肠外用药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Right coronary ischaemia caused by a sinus of Valsalva aneurysm improved by releasing mechanical stretch: A case report Right coronary ischaemia caused by a sinus of Valsalva aneurysm improved by releasing mechanical stretch: A case report ST-elevation myocardial infarction from septic embolism secondary to prosthetic aortic valve endocarditis – a case report Management of a Pregnant Woman with Marfan Syndrome and Aortic Root and Aberrant Right Subclavian Artery Aneurysm: A Case Report Nuclear Envelope Lamin-Related Dilated Cardiomyopathy: Case Series Including Histopathology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1